【以色列 AI 生物技术公司 Nucleai 完成 1400 万美元 B+ 轮融资】
以色列初创公司 Nucleai，一家专注于 AI 空间生物标志物分析的领先企业，于本周三宣布成功获得 1400 万美元的 B+ 轮融资。本轮融资由知名投资机构 M Ventures 领衔，包括 Section 32、Sanofi Ventures、Debiopharm、复星锐正资本、Vertex Ventures Israel 和 Grove Ventures 在内的现有投资者也积极参与了投资。
Nucleai 利用先进的人工智能和机器学习技术，对细胞和组织层面的病理图像及空间数据进行深度分析，以期预测疾病的治疗效果和患者预后。这一创新技术有望为精准医疗领域带来革命性的突破，提高诊断的准确性和治疗的个性化程度。
公司创始人表示，新注入的资金将主要用于进一步研发其 AI 平台，加速产品商业化进程，以及扩大全球市场布局。Nucleai 的技术进展和资本支持，不仅展示了人工智能在生物医学领域的巨大潜力，也为全球医疗健康行业的发展注入了新的活力。
英语如下：
**News Title:** “Nucleai, an AI Biomarker Analysis Company, Raises $14 Million in B+ Round, Pioneering a New Era in Pathological Image Intelligence Analysis”
**Keywords:** AI bioanalysis, Nucleai funding, pathological image analysis
**News Content:**
**Israeli AI Biotech Company Nucleai Secures $14 Million in B+ Funding Round**
Israeli startup Nucleai, a leading company in AI spatial biomarker analysis, announced on Wednesday that it has successfully raised $14 million in its B+ funding round. The round was led by prominent investor M Ventures, with participation from existing investors including Section 32, Sanofi Ventures, Debiopharm, Fosun RZ Capital, Vertex Ventures Israel, and Grove Ventures.
Nucleai employs advanced artificial intelligence and machine learning techniques to conduct in-depth analysis of pathological images and spatial data at the cellular and tissue levels, aiming to predict disease treatment response and patient prognosis. This innovative technology holds the potential for a revolutionary breakthrough in precision medicine, enhancing diagnostic accuracy and personalization of treatments.
The company’s founders stated that the newly injected funds will primarily be used to further develop their AI platform, accelerate commercialization efforts, and expand their global market presence. Nucleai’s technological advancements and capital support not only demonstrate the significant potential of AI in the biomedical field but also infuse new vitality into the global healthcare industry.
【来源】https://www.calcalistech.com/ctechnews/article/r11brac1a
Views: 1